Glioblastoma is our first target indication but we also have the intention of developing a pipeline of other neuro-oncology indications in the future.
Glioblastoma is the most common primary brain cancer in adults and the most lethal1
It is an incredibly treatment-resistant cancer, with limited options available to patients2
5-year survival rate despite intensive treatment that includes surgery, chemotherapy & radiotherapy3
Of primary brain tumours are classified as Glioblastoma4
Innovation in the space has been lagging behind other cancer treatments for decades5
Since the last major breakthrough in glioblastoma treatment6
Median overall survival for glioblastoma patients with the current standard of care7
Glioblastoma can occur in any age group, with the frequency of cases increasing with age8
Over 3,000 new cases in the UK alone every year9
Electric Field Therapy is a new modality in treating cancer.
Utilising electrical fields at specific frequencies can interrupt normal cancer cell growth cycles, slowing down tumour growth.
This mechanism has been approved for and has demonstrated its clinical efficacy in glioblastoma.
At QV Bioelectronics, our aim is to develop the full potential of this technology.
GRACE is an innovative implanted device that delivers electric field therapy directly to the tumour resection margins, where 90% of GBM recurrence takes place
By delivering through an implant, GRACE will aim to deliver long, better quality lives for GBM patients by providing continuous therapy while minimising its effect on patient quality of life.
*GRACE is an experimental device not currently approved for human use and is still several years away from being utilised in the clinic.
© 2024 QV Bioelectronics Ltd | All rights reserved.